Table 2.
Clinicopathologic characteristics of patients and hepatic observations
| Characteristic | Value (%) |
|---|---|
| Patient (n = 379) | |
| Mean age (years)a | 58.1 ± 10.4 |
| Sex, male/female | 265/114 |
| Cirrhosis (%) | 314 (82.8%) |
| Cause of liver disease (%) | |
| Hepatitis B virus | 301 (79.4) |
| Hepatitis C virus | 38 (10.0) |
| Alcohol consumption | 9 (2.4) |
| Autoimmune disorders | 4 (1.1) |
| NASH | 1 (0.3) |
| Hepatitis B and C virus | 6 (1.6) |
| Cirrhosis of unknown cause | 20 (5.3) |
| Number of observations per patient (%) | |
| 1 | 341 (90.0) |
| 2 | 29 (7.7) |
| 3 | 9 (2.4) |
| Observation (n = 426) | |
| Size (mm) | |
| Over allb | 27 (16–52) |
| HCCa | 34.7 ± 27.3 |
| Non-HCC malignancyb | 45 (27–66) |
| Benign lesionb | 22 (14–44) |
| Final diagnosis (%) | |
| HCC | 250 (58.7) |
| Non-HCC malignancy | 88 (20.7) |
| ICC | 41 (9.6) |
| CHC | 13 (3.1) |
| Metastasis | 23 (5.4) |
| Sarcomatoid carcinoma | 6 (1.4) |
| Cystadenocarcinoma | 3 (0.7) |
| Neuroendocrine carcinoma | 1 (0.2) |
| Haemangiosarcoma | 1 (0.2) |
| Benign lesion | 88 (20.7) |
| Haemangioma | 16 (3.8) |
| DN | 34 (8.0) |
| RN | 11 (2.6) |
| FNH | 9 (2.1) |
| Adenoma or adenomatoid hyperplasia | 6 (1.4) |
| Abscess | 4 (0.9) |
| Angiomyolipoma | 2 (0.5) |
| Epithelioid angiomyolipoma | 3 (0.7) |
| Inflammatory nodule | 1 (0.2) |
| Lipomyoma | 1(0.2) |
| Ematoma | 1 (0.2) |
| Standard reference of diagnosis (%) | |
| Surgical pathology | 199 (46.7) |
| Biopsy pathology | 227 (53.3) |
Unless stated otherwise, data are presented as the number of patients or observations with the percentage in parentheses. aData are presented as the mean ± standard deviation; bData are presented as the median (interquartile range). NASHNonalcoholic steatohepatitis, HCC Hepatocellular carcinoma, ICC Intrahepatic cholangiocarcinoma, CHC Combined hepatocellular cholangiocarcinoma, DN Dysplastic nodule, RN Regenerative nodule, FNH Focal nodular hyperplasia